Congo began administering the Ervebo vaccine to healthcare staff in Bunia, the epicenter of the fastest-growing Ebola outbreak in history, according to regional health authorities. The rollout targets front-line workers responding to the epidemic caused by the Bundibugyo virus, a strain that currently lacks any licensed vaccine or specific treatment.
Bunia Vaccination Drive Targets Front-Line Health Workers
Health authorities launched the vaccination campaign in Bunia to protect personnel considered deeply involved in the response, according to Ituri military governor Maj. Gen. Gaby Kasongo Mulumba. The current outbreak is concentrated in Ituri province and represents the deadliest of the 17 past Ebola outbreaks recorded in the country.
Government figures cited by the Associated Press show the epidemic has produced 7,541 confirmed cases and 3,639 deaths, alongside 1,823 recoveries. The World Health Organization reported that the virus continues to spread rapidly amid severe insecurity, displacement, population movements, and an active health workers’ strike.
Did You Know?
The World Health Organization stated that the ongoing outbreak in Congo is on track to surpass the 2014-2016 West Africa Ebola epidemic, the deadliest on record, which killed more than 11,000 people primarily in Guinea, Liberia, and Sierra Leone.
Ervebo Deployment Under Compassionate-Use Programs
The vaccine being administered is Ervebo, a product licensed for use against the Zaire strain of the Ebola virus. Because the current outbreak stems from the Bundibugyo virus—which has no licensed countermeasures—authorities are utilizing Ervebo under a compassionate-use program, as reported by health officials.
Health authorities note that Ervebo could offer cross-protection because the two viral strains are related. However, clinical trials remain underway to definitively establish whether the vaccine prevents illness in people infected with the Bundibugyo variant.
Dosage Allocation and Clinical Trials
The World Health Organization approved 70,000 total doses of Ervebo for deployment in Congo. Out of this total supply, approximately 50,000 doses are designated for front-line and healthcare workers. The remaining 20,000 doses are allocated for clinical trials designed to evaluate protection levels against the Bundibugyo strain.
Placide Mbala Kingebeni, Africa CDC’s director for research, clinical trials and innovation, stated that data will be systematically collected during the rollout to measure performance. Concurrently, human trials for a new vaccine specifically targeting the Bundibugyo strain have reached Phase I through the University Oxford’s Vaccine Group and Moderna.
Logistical Hurdles and Vaccinee Perspectives
The vaccination campaign spans multiple provinces. In addition to the Ituri and North Kivu drives targeting 20,000 workers over six to nine months, a separate rollout launched in Kisangani covering 14 health zones across Tshopo, Bas-Uele, and Haut-Uele provinces, according to Health Minister Roger Kamba.
Health workers in Bunia face complicated decisions regarding repeat inoculations. Dr. Jeannot Elua told the Associated Press that staff view the vaccine as beneficial while noting mandatory participation rules. Meanwhile, Dr. Jean Paul Uzele questioned whether a second round of vaccination is necessary after receiving Ervebo during the country’s 10th outbreak.
Frequently Asked Questions
Which virus is causing the current Ebola outbreak in Congo?
The current outbreak is caused by the Bundibugyo virus, a strain that currently has no licensed vaccine or specific treatment.
What vaccine is being used in the initial rollout?
Health authorities are administering the Ervebo vaccine under a compassionate-use program, utilizing supplies originally licensed for the Zaire strain.
How many doses of Ervebo have been approved for Congo?
The World Health Organization approved 70,000 doses of Ervebo, with over 50,000 dedicated to front-line workers and 20,000 reserved for clinical trials.
Stay Informed on Global Health Developments
Explore our latest reporting and analysis on international health crises and outbreak responses. Share your thoughts or questions in the comments below.